Spero Therapeutics appoints Kathleen Tregoning to Board; Jean-François Formela resigns

Spero Therapeutics, Inc.

Jean-François Formela resigned from the Board effective Oct 11, 2021, as part of a planned transition.
Kathleen Tregoning appointed to fill the vacancy, effective Oct 11, 2021.
Tregoning brings over 20 years of biotech and public policy experience; currently Chief Corporate Affairs Officer at Cerevel Therapeutics.
Former executive at Biogen and Sanofi, and former congressional staff member.
Tregoning will serve as Class III director up for reelection at 2023 annual meeting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jean-François Formela

Director

SPRO · Spero Therapeutics, Inc.

Effective: 2021-10-11
Successor: Kathleen Tregoning
Filed: October 12, 2021, 7:59 PM ET

On October 11, 2021, Jean-François Formela, M.D. notified the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) of his resignation from the Board and the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective as of October 11, 2021.

Appointed

Kathleen Tregoning

Director

SPRO · Spero Therapeutics, Inc.

Effective: 2021-10-11
Filed: October 12, 2021, 7:59 PM ET

On October 11, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Kathleen Tregoning to the Board, effective as of October 11, 2021, to fill the vacancy created by Dr. Formela’s resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jean-François Formela resigned as Director at Spero Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 11, 2021, Jean-François Formela, M.D. notified the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) of his resignation from the Board and the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective as of October 11, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kathleen Tregoning was appointed as Director at Spero Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 11, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Kathleen Tregoning to the Board, effective as of October 11, 2021, to fill the vacancy created by Dr. Formela’s resignation.

View on SEC.gov

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-296407

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.